New $3.2B FUJIFILM facility signals shift in biotech manufacturing power to the US
Subscribe to our free newsletter today to keep up to date with the latest manufacturing news.
FUJIFILM Biotechnologies has officially opened its commercial‑scale cell culture manufacturing facility in Holly Springs, North Carolina. The first phase of the $3.2 billion site brings eight 20,000‑liter mammalian cell culture bioreactors online, with plans to expand to sixteen reactors by 2026. The site currently employs over 680 people, with a target of 1,400 roles by 2031.
A new flagship in the US biomanufacturing map
The Holly Springs launch places FUJIFILM at the heart of a broader reorientation of biopharma manufacturing in the United States. Demand for biologics, especially monoclonal antibodies and other complex therapeutics, is growing rapidly, and CDMO providers are investing heavily to match. The biologics CDMO market is forecast to more than double in size over this decade, with North America capturing a leading share of that growth.
The decision to build one of the largest cell culture sites in North America reflects not just scale, but strategy. With this facility, FUJIFILM reduces dependence on overseas capacity. It gives pharmaceutical partners closer proximity to U.S. regulatory and supply environments. In doing this it nudges the entire manufacturing balance more toward domestic production.
Strengthening the North Carolina cluster
North Carolina already boasts a mature biopharma manufacturing ecosystem. The state supports more than 100 biopharma manufacturing sites and hosts a top tier share of life sciences employment. The state’s community college system and universities have invested in training programs tailored to biotech production, a key enabler of rapid growth in facility expansion.
FUJIFILM is not alone here. The state attracted $10.8 billion in life sciences investment in 2024, in part through incentives, low corporate tax rates, and a favorable cost base. Roche recently pledged $700 million in its own Holly Springs expansion. Biogen has likewise committed further investments to its North Carolina footprint.
With several major CDMOs clustered in the state, manufacturers and drug sponsors gain efficiency through proximity, shared talent pools, and supply chain synergies.
Impacts on manufacturing landscape
The Holly Springs facility shifts the competitive dynamics of global biomanufacturing in multiple ways.
First, it accelerates the onshoring trend. Companies are increasingly reluctant to rely on offshore capacity given supply chain disruptions, regulatory risk, and geopolitical pressures. Having high‑capacity U.S. sites gives clients flexibility and resilience.
Second, it raises the bar in cost, scale, and technology expectation. Massive modular designs like FUJIFILM’s kojoX approach enabled rapid design execution and replication, cutting development times. As more CDMOs adopt these modular, scalable architectures, economies of scale deepen, pushing smaller facilities to either specialize or consolidate.
Third, it intensifies competition for talent. The drive to fill thousands of high‑skill roles in North Carolina will steepen the demand curve for biotech engineers, downstream process specialists, and GMP operations staff. The state’s workforce development programs will be essential, but gaps may emerge.
Fourth, it may reshape site selection criteria. Factors like energy sustainability, local incentives, permitting agility, and existing biotech ecosystems will weigh more heavily. FUJIFILM’s commitment to offset electrical emissions through renewable certificates underscores the importance of ESG considerations.
Lastly, downstream industries will feel ripple effects. Suppliers of specialized bioprocess equipment, consumables, single‑use systems, and analytics will see intensified demand in the region. The supporting supply chain may increasingly locate nearby to service the cluster.
The Holly Springs site is more than a new asset, it is a landmark in a shifting era for biopharma manufacturing.
Sources